Physician profile
Mark D Bowden
NPI 1669580668
$3,754.00
in general payments reported to CMS, 2019-2025
33 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $646 · 2020: $612 · 2021: $1,166 · 2022: $1,099 · 2023: $202 · 2024: $30.16.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $232.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $231.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $636.69 | 2019-2022 | |
| Glaxosmithkline, LLC. | $485.42 | 2019-2023 | Shingrix, Arexvy |
| Novo Nordisk INC | $469.86 | 2019-2023 | Ozempic, Rybelsus |
| Amarin Pharma, INC. | $281.01 | 2019-2022 | |
| Lilly USA, LLC | $209.45 | 2019-2023 | Mounjaro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $206.76 | 2020-2022 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $155.67 | 2022 | |
| Merck Sharp & Dohme LLC | $108.20 | 2019-2022 | |
| Eisai INC. | $105.88 | 2020-2021 | |
| Sanofi-Aventis U.S. LLC | $104.71 | 2019-2022 | |
| Abbott Laboratories | $104.32 | 2020-2023 | Freestyle Libre 3 |
| Amgen INC. | $103.43 | 2020-2024 | Repatha, Otezla |
| Pfizer INC. | $94.55 | 2019-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $80.21 | 2021-2022 | |
| Abbvie INC. | $78.74 | 2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $56.63 | 2020-2022 | |
| Horizon Therapeutics Plc | $49.10 | 2021 | |
| Novartis Pharmaceuticals Corporation | $45.78 | 2022-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $45.05 | 2022 | |
| Janssen Pharmaceuticals, INC | $44.20 | 2019-2021 | |
| Idorsia Pharmaceuticals US INC | $39.95 | 2022-2023 | Quviviq |
| Mylan Specialty L.P. | $35.44 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $33.74 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $29.34 | 2021 | |
| Protega Pharmaceutials INC | $24.60 | 2022 | |
| Dexcom, INC. | $23.41 | 2021 | |
| Exact Sciences Corporation | $18.11 | 2023 | Cologuard Collection Kit |
| Nestle Healthcare Nutrition INC. | $17.87 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $15.97 | 2021 | |
| Xeris Pharmaceuticals, INC. | $13.22 | 2021 | |
| Esperion Therapeutics, INC. | $13.04 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $11.98 | 2022 | |
| Fidia Pharma USA INC. | $11.67 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Bowden listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.